title: Screening for neuroblastoma in France: methodological aspects and preliminary observations.
abstract: A pilot study of neuroblastoma mass screening was initiated in January 1990 in the Rhône French district. The expected number of births per year is 26,000. The study is designed for a 5-year period with three major goals: 1) measurement of the compliance rate of a voluntary test at 4 months of age; 2) evaluation of the technical value of high-pressure liquid chromatography (HPLC) as a screening method; and 3) detailed biological characterization of all detected tumors. 61,551 children were screened between May 1, 1990 and December 31, 1993. Participation was 69% in 1990, 81.5% in 1991, and over 83% in 1992. HPLC was a satisfactory assay method. The number of clinical examinations required for positive tests as defined in the protocol is 1 per 3,621 tests. The false positive rate is 1 per 3,583 tests. Eight neuroblastomas were discovered by-screening (one stage I, three stage II, one stage III, three stage IVs). All are alive and well but were good prognosis cases according to the main prognostic factors. Five patients were discovered before screening (so called Halo effect): one stage I, one stage III, three stage IVs. One died of disease and four are alive in complete remission after treatment. Two patients were false negative (one stage III with N-myc amplification, one stage IV with bad prognosis features) and three cases of neuroblastoma were missed because of noncompliance with the screening program. This pilot study concludes on the feasibility of a mass screening program in France. The estimated cumulative incidence of neuroblastoma at 3 years is 1 per 4,375 living births and overdiagnosis is probable. All the detected cases were of good prognosis and the false negative ones were poor prognosis cases.
authors.affiliation: Service de Biologie Générale et de Neurobiologie, C.H.S. le Vinatier, Bron, France.
authors.forename: F
authors.initials: F
authors.lastname: Chauvin
authors.forename: P
authors.initials: P
authors.lastname: Mathieu
authors.forename: D
authors.initials: D
authors.lastname: Frappaz
authors.forename: C
authors.initials: C
authors.lastname: Lasset
authors.forename: M C
authors.initials: MC
authors.lastname: Favrot
authors.forename: J
authors.initials: J
authors.lastname: Greffe
authors.forename: J
authors.initials: J
authors.lastname: Esteve
authors.forename: P
authors.initials: P
authors.lastname: Thiesse
authors.forename: V
authors.initials: V
authors.lastname: Combaret
authors.forename: P
authors.initials: P
authors.lastname: Chauvot
authors.forename: R
authors.initials: R
authors.lastname: Boschetti
authors.forename: L
authors.initials: L
authors.lastname: David
authors.forename: M
authors.initials: M
authors.lastname: Brunat-Mentigny
authors.forename: T
authors.initials: T
authors.lastname: Philip
mesh_terms: D002675:Child, Preschool; D002851:Chromatography, High Pressure Liquid; D005188:False Negative Reactions; D005189:False Positive Reactions; D005240:Feasibility Studies; D005602:France / Q000453:epidemiology; D006719:Homovanillic Acid / Q000652:urine; D006801:Humans; D007223:Infant; D008403:Mass Screening / Q000379:methods*; D009367:Neoplasm Staging; D009447:Neuroblastoma / Q000453:epidemiology / Q000517:prevention & control* / Q000652:urine; D010865:Pilot Projects; D012680:Sensitivity and Specificity; D014642:Vanilmandelic Acid / Q000652:urine
chemical_list: D014642:Vanilmandelic Acid; D006719:Homovanillic Acid